Sanofi to launch independent active drug ingredients business

Sanofi plans to create a standalone company dedicated to producing active pharmaceutical ingredients (API) and will decide whether to list it on Euronext Paris by 2022. Sanofi said the new group will be headquartered in France and target sales estimated at about 1 billion euros (USD 1.1 billion) by 2022. The idea is to create a European API production company that would be able to supply capacities for the continent and beyond, while balancing the industry's reliance on APIs from Asia.